Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Twist Bioscience (TWST) Stock Price & Analysis

1,310 Followers

TWST Stock Chart & Stats

$114.22-$8.37(-6.83%)
At close: 4:00 PM EST
$125$150$175$200Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$93.68 - $114.97
52-Week Range
$23.30 - $219.71
Previous Close
$122.59
Volume
N/A
Average Volume (3M)
2.89M
Market Cap
$8.07B
Enterprise Value
$12.12B
Total Cash (Recent Filing)
$166.84M
Total Debt (Recent Filing)
$93.59M
Price to Earnings (P/E)
―
Beta
1.69
Next Earnings
Jan 29, 2027 (Est.)
EPS Estimate
-0.37
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Sustained Revenue Growth

Sustained double-digit revenue growth and raised annual guidance indicate expanding demand across Twist’s synthetic biology, NGS, and therapeutics offerings. Continued growth can improve operating leverage, support investment in the platform, and strengthen the company’s position with life-science customers over the next several quarters.

Improving Manufacturing Efficiency And Margins

Large improvements in manufacturing cost, waste, turnaround time, and capacity support a more scalable operating model. These efficiencies can help preserve gross-margin gains as revenue expands, increase throughput for complex customer orders, and improve the long-term economics of Twist’s silicon-based DNA platform.

Strengthened Funding Capacity

The capital raise materially expands resources available for research, manufacturing capacity, product development, and working capital. This funding can support execution of Twist’s growth strategy and provide greater flexibility while the company works toward sustainable profitability and broader commercial adoption.

Bears Say

Persistent Cash Burn

Persistent negative operating and free cash flow means the business has not yet funded its operations internally. Continued cash consumption can require reliance on external capital, limit financial flexibility, and make successful execution of the growth plan increasingly dependent on reaching positive operating cash flow.

Profitability Remains Unproven

Despite improving revenue and gross margin, Twist remains substantially unprofitable at both the net income and operating levels. The company’s EBITDA breakeven target is still prospective, so elevated expenses and any slower growth could delay operating leverage and extend the period of losses.

Order Conversion And Competitive Risk

Separation between order activity and recognized revenue can make growth less predictable, particularly for large AI-driven orders. Competitive actions and discounting may also pressure sequencing and protein-business mix or average selling prices, reducing the consistency of revenue conversion and margins.

Twist Bioscience News

TWST FAQ

What was Twist Bioscience’s price range in the past 12 months?
Twist Bioscience lowest stock price was $23.30 and its highest was $219.71 in the past 12 months.
What is Twist Bioscience’s market cap?
Twist Bioscience’s market cap is $8.07B.
When is Twist Bioscience’s upcoming earnings report date?
Twist Bioscience’s next earnings report is estimated for Jan 29, 2027 (not yet confirmed), which is in 77 days.
How were Twist Bioscience’s earnings last quarter?
Twist Bioscience released its earnings results on Nov 12, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.387 by $0.067.
Is Twist Bioscience overvalued?
According to Wall Street analysts Twist Bioscience’s price is currently Undervalued.
Does Twist Bioscience pay dividends?
Twist Bioscience does not currently pay dividends.
What is Twist Bioscience’s EPS estimate?
Twist Bioscience’s EPS estimate is -0.37.
How many shares outstanding does Twist Bioscience have?
Twist Bioscience has 65,832,420 shares outstanding.
What happened to Twist Bioscience’s price movement after its last earnings report?
Twist Bioscience reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.387. Following the earnings report the stock price went down -6.828%.
Which hedge fund is a major shareholder of Twist Bioscience?
Hedge funds hold Twist Bioscience shares: the largest hedge-fund position in Twist Bioscience is 71,886,850 shares, and hedge funds decreased their holdings by 3.5M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology